Stemline Therapeutics

📍 New York, United States🗓 Founded 2003👥 352 employees💰 Last funded 2012
Biotechnology🌐 stemline.com
Website LinkedIn
Stemline is a commercial-stage biopharmaceutical company committed to applying our scientific leadership and commercial expertise to transform the lives of patients with cancer. ELZONRIS a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN. In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). Inspired by the goal to improve outcomes for patients with unmet medical needs, Stemline is driven to discover and develop innovative therapeutics for the treatment of cancer. Currently our clinical-stage product candidates in include ELZONRIS, SL-701 and SL801.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2003
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Stemline Therapeutics?
Stemline Therapeutics has 1 investors on record on gritt.io and 1 late-stage investors.
When did Stemline Therapeutics last raise funding?
The most recent investment in Stemline Therapeutics recorded on gritt.io was in 2012.
When was Stemline Therapeutics founded?
Stemline Therapeutics was founded in 2003.
What industry is Stemline Therapeutics in?
Stemline Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Stemline Therapeutics based?
Stemline Therapeutics is headquartered in New York, United States.